Core Viewpoint - The company is strategically acquiring Jilin Youben to enhance its capabilities in African swine fever vaccine research and production, aiming to increase market share and core competitiveness in the animal vaccine sector [1]. Group 1: Acquisition and Strategic Goals - The acquisition of Jilin Youben is aimed at improving the speed of research and production transformation for African swine fever vaccines [1]. - The company plans to expand its market share in the animal vaccine field through this acquisition [1]. Group 2: Compliance and Safety Upgrades - Jilin Youben and Jinhe Youben have upgraded their facilities to meet the safety requirements for vaccine production and testing, achieving biosafety level three compliance by specific dates in 2025 [1]. - By the end of Q3 2025, the company will have met all necessary qualifications for conducting clinical trials for the African swine fever vaccine [1]. Group 3: Challenges in Vaccine Development - Jilin Youben is facing challenges in finalizing a technology licensing contract with the patent transferor, which is crucial for the production and testing of the African swine fever vaccine [2]. - The company has recognized the high technical difficulty and lengthy regulatory approval process associated with African swine fever vaccine development, leading to uncertainties in project timelines and performance [2]. - As a result of these challenges, the company has decided to suspend the research and application of the freeze-dried inactivated African swine fever vaccine [2].

Core Viewpoint - The company has decided to suspend the research and application of the African Swine Fever freeze-dried inactivated vaccine due to uncertainties in project progress and high R&D difficulties [1] Group 1: Company Actions - On January 30, 2026, the company's board of directors approved the suspension of the African Swine Fever vaccine project [1] - The company’s subsidiary, Jinhai Youben, acquired 60% equity of Jilin Youben for 288 million yuan to enter the African Swine Fever vaccine research and production [1] Group 2: Project Status - As of the end of the third quarter of 2025, all relevant qualifications for the project had met the requirements [1] - Disagreements with the patent transferor over key terms have led to uncertainties in project progress [1] Group 3: Financial Implications - The suspension of the project will result in goodwill impairment but will not have a significant adverse impact on existing business operations [1]

南方财经1月29日电，瑞普生物1月29日在互动平台表示，公司目前无尼帕病毒相关的针对性疫苗、药 品，将持续关注相关病毒动态，合理评估研发机会。 ...

每经AI快讯，银河证券指出，强调生猪养殖行业的攻守兼备布局机会，基于能繁母猪作用值及养殖效 率的考虑，今年猪价同比下行，期间或有所反弹表现；综合考虑政策去产能以及行业亏损去产能，重点 关注成本边际变化显著、资金面良好的优质猪企。2）宠物食品行业处成长过程中，优质企业市占率呈 提升趋势。3）可关注养殖链后周期及动物疫苗相关企业。4）考虑黄羽鸡自身供给相对低位，叠加需求 端的改善预期。 ...

Market Overview - The A-share market experienced a collective adjustment, with the Shanghai Composite Index rising by 0.09%, while the Shenzhen Component Index fell by 0.85%, and the ChiNext Index decreased by 0.91% [1] - The total trading volume in the three markets reached 32,806 billion yuan, an increase of 1,625 billion yuan compared to the previous day, with over 3,700 stocks declining [1] Sector Performance - The sectors that saw gains included gold, non-ferrous metals, animal vaccines, insurance, oil and gas extraction and services, chemicals, and pork, with significant increases [1] - Conversely, sectors that faced declines included commercial aerospace, large aircraft, military equipment, photolithography machines, semiconductors, robotics, and quantum technology, with notable losses [1] Notable Stocks and Events - International gold prices surpassed 5,000 USD for the first time, leading to a surge in gold stocks, with companies like Western Gold and Zhaojin Gold hitting the daily limit [1] - The recent Nipah virus outbreak in India caused a collective rise in the biopharmaceutical vaccine sector, with stocks like Hualan Biological and Zhijiang Biological also reaching the daily limit [1] - Oil and gas stocks performed actively, with China National Offshore Oil Corporation reaching a historical high during trading [1] - Other sectors such as chemicals, insurance, and pork also showed positive performance during the trading session [1] - On the downside, the commercial aerospace sector saw a collective downturn, with companies like Haige Communication and Shenjian Co. hitting the daily limit down [1] - The semiconductor equipment sector also performed poorly, with companies like Zhichun Technology facing a limit down [1]

Group 1 - The core viewpoint of the news is that Haili Biological experienced a decline in stock price and trading volume, with significant details on financing and stockholder changes [1][2] Group 2 - On January 15, Haili Biological's stock fell by 1.83%, with a trading volume of 83.6 million yuan [1] - The financing data shows that on the same day, Haili Biological had a financing purchase amount of 9.52 million yuan, with a net financing purchase of 2.78 million yuan [1] - As of January 15, the total balance of margin trading for Haili Biological was 212 million yuan, with the financing balance accounting for 5.06% of the circulating market value, indicating a low level compared to the past year [1] - In terms of securities lending, Haili Biological had a securities lending repayment of 1,300 shares and a securities lending sell of 2,000 shares, with a total lending balance of 44.05 million yuan, also at a low level compared to the past year [1] Group 3 - As of September 30, the number of shareholders for Haili Biological increased to 33,800, a rise of 7.16%, while the average circulating shares per person decreased by 6.68% [2] - For the period from January to September 2025, Haili Biological reported a revenue of 150 million yuan, a year-on-year decrease of 14.15%, while the net profit attributable to the parent company was 20.33 million yuan, reflecting a slight increase of 0.77% [2] - Haili Biological has distributed a total of 209 million yuan in dividends since its A-share listing, with 107 million yuan distributed over the past three years [2] - Among the top ten circulating shareholders as of September 30, 2025, Guotai Zhongzheng Livestock Breeding ETF ranked as the fifth largest shareholder, increasing its holdings by 3.70 million shares to 10.23 million shares [2]

Core Viewpoint - The company is actively seizing strategic opportunities from the "Belt and Road" initiative and the construction of the Xinjiang Free Trade Zone to steadily advance its overseas business expansion [1] Group 1: Overseas Business Expansion - The company's overseas business primarily focuses on two core sectors: "feed" and "animal vaccines," which are still in the initial and expansion stages [1] - Future plans include diversifying into aquaculture, feed, oil, and trade through multiple channels [1] - The company will cautiously assess its business goals based on market development progress, local demand, and its own production capacity [1] Group 2: Market Challenges - The expansion of overseas business is influenced by multiple factors, including target market policies, competitive environment, and international trade conditions, which introduce uncertainties [1]

Group 1 - The company has submitted a clinical trial application for its African swine fever subunit vaccine developed in collaboration with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences [2] - The company will fulfill its information disclosure obligations in a timely manner if the relevant matters meet the standards for information disclosure [2]

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

Group 1: Company Overview - The report focuses on Bio Co., Ltd. (600201), highlighting its potential breakthrough with the African Swine Fever vaccine, which is expected to reshape its competitive advantage and growth momentum [3][4]. - The recommendation logic emphasizes the company's strong R&D barriers, rich product pipeline, and the recent clinical approval of the ASF vaccine, which could become the main growth driver over the next 3-5 years [3][4]. Group 2: Financial Projections - Projected revenues for Bio Co., Ltd. from 2025 to 2027 are estimated at 1,603.76 million, 2,035.36 million, and 2,520.85 million yuan, with year-on-year growth rates of 27.74%, 26.91%, and 24.85% respectively [4]. - The net profit attributable to the parent company is forecasted to be 303.45 million, 397.65 million, and 491.31 million yuan for the same period, with growth rates of 178.44%, 31.04%, and 23.55% respectively [4]. Group 3: Catalysts and Drivers - Key catalysts include breakthroughs in the ASF vaccine development and advancements in the mRNA vaccine for feline infectious peritonitis [4]. - The driving factors for growth are the leading progress in ASF vaccine development, a solid position in foot-and-mouth disease, rapid expansion in the pet sector, and ongoing overseas market development [3][4]. Group 4: Market Position and Strategy - The company is expected to exceed performance expectations due to the clinical approval of the ASF vaccine, diversified product launches, and rapid overseas market expansion [3]. - The strategy includes leveraging marketing support, online channel development, and international market penetration to drive revenue growth [3].